Home LiteratureArticle Details
PMID: 18437155 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators.

Nature reviews. Immunology ·Vol. 8 ·No. 5 ·2008-05-00 ·Pages 349-61

Serhan CN, Chiang N, Van Dyke TE

Abstract

Active resolution of acute inflammation is a previously unrecognized interface between innate and adaptive immunity. Once thought to be a passive process, the resolution of inflammation is now shown to involve active biochemical programmes that enable inflamed tissues to return to homeostasis. This Review presents new cellular and molecular mechanisms for the resolution of inflammation, revealing key roles for eicosanoids, such as lipoxins, and recently discovered families of endogenous chemical mediators, termed resolvins and protectins. These mediators have anti-inflammatory and pro-resolution properties, thereby protecting organs from collateral damage, stimulating the clearance of inflammatory debris and promoting mucosal antimicrobial defence.

MeSH Terms
Animals CD59 Antigens/physiology Eicosanoids/physiology Eicosapentaenoic Acid/analogs & derivatives,physiology Humans Immunity, Active Immunity, Innate Inflammation/immunology Inflammation Mediators/physiology Lipoxins/physiology Mucous Membrane/immunology,microbiology Signal Transduction
Chemicals
CD59 Antigens Eicosanoids Inflammation Mediators Lipoxins Eicosapentaenoic Acid
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Serhan Charles N
Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. cnserhan@zeus.bwh.harvard.edu
Chiang Nan
Van Dyke Thomas E
References (112)
112 references, click to expand
  1. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction.
    J Exp Med. 1996 Jan 1;183(1):137-46 PMID: 8551217
  2. Lipoxin generation by permeabilized human platelets.
    Biochemistry. 1992 Sep 8;31(35):8269-77 PMID: 1381961
  3. Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions.
    Blood. 1999 Dec 15;94(12):4132-42 PMID: 10590058
  4. Inflammatory resolution: new opportunities for drug discovery.
    Nat Rev Drug Discov. 2004 May;3(5):401-16 PMID: 15136788
  5. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1.
    J Exp Med. 2005 Mar 7;201(5):713-22 PMID: 15753205
  6. Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4.
    FASEB J. 2002 Dec;16(14):1937-9 PMID: 12368230
  7. Mechanisms underlying inflammatory edema: the importance of synergism between prostaglandins, leukotrienes, and complement-derived peptides.
    Adv Prostaglandin Thromboxane Leukot Res. 1983;11:33-7 PMID: 6221544
  8. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4).
    Nat Med. 2002 Sep;8(9):1018-23 PMID: 12172542
  9. Resolution of inflammation: state of the art, definitions and terms.
    FASEB J. 2007 Feb;21(2):325-32 PMID: 17267386
  10. Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins-Mediator lipidomic analysis.
    Prostaglandins Other Lipid Mediat. 2005 Dec;78(1-4):107-16 PMID: 16303609
  11. Lipoxin biosynthesis in inflammatory bowel disease.
    Prostaglandins Other Lipid Mediat. 2006 Mar;79(1-2):84-92 PMID: 16516812
  12. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA.
    FASEB J. 2006 Dec;20(14):2537-9 PMID: 17056761
  13. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness.
    J Immunol. 2007 Jan 1;178(1):496-502 PMID: 17182589
  14. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor.
    J Biol Chem. 1997 Mar 14;272(11):6972-8 PMID: 9054386
  15. Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis.
    Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11276-81 PMID: 16847262
  16. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction.
    Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15736-41 PMID: 15505205
  17. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity.
    Nat Immunol. 2002 Jan;3(1):76-82 PMID: 11743584
  18. Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction.
    Biochemistry. 1995 Dec 26;34(51):16678-86 PMID: 8527441
  19. Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs.
    J Clin Invest. 1998 May 1;101(9):1860-9 PMID: 9576749
  20. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids.
    Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12499-504 PMID: 16888035
  21. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation.
    J Exp Med. 2004 Jul 5;200(1):69-78 PMID: 15238606
  22. Mechanisms of action of docosahexaenoic acid in the nervous system.
    Lipids. 2001 Sep;36(9):945-59 PMID: 11724467
  23. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi-LXA4 block allergen-induced eosinophil trafficking.
    J Immunol. 2000 Mar 1;164(5):2267-71 PMID: 10679058
  24. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2.
    Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20979-84 PMID: 18077391
  25. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease.
    J Clin Invest. 2005 Oct;115(10):2774-83 PMID: 16151530
  26. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators.
    J Immunol. 2003 Dec 15;171(12):6856-65 PMID: 14662892
  27. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo.
    Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8247-52 PMID: 10393980
  28. Lipoxins stimulate prostacyclin generation by human endothelial cells.
    FEBS Lett. 1989 Mar 13;245(1-2):167-72 PMID: 2494071
  29. Characterization of human neutrophil and endothelial cell ligand-operated extracellular acidification rate by microphysiometry: impact of reoxygenation.
    J Pharmacol Exp Ther. 1998 Apr;285(1):252-61 PMID: 9536019
  30. Prostaglandins, bioassay and inflammation.
    Br J Pharmacol. 2006 Jan;147 Suppl 1:S182-92 PMID: 16402103
  31. Lipoxins are potential endogenous antiinflammatory mediators in asthma.
    Am J Respir Crit Care Med. 2002 Jun 1;165(11):1531-5 PMID: 12045128
  32. Suppression of acute and chronic inflammation by orally administered prostaglandins.
    Arthritis Rheum. 1981 Sep;24(9):1151-8 PMID: 6458304
  33. A magic bullet for mucosal protection...and aspirin is the trigger!
    Trends Pharmacol Sci. 2003 Jul;24(7):323-6 PMID: 12871661
  34. Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue, ZK 118.182.
    Eur J Pharmacol. 1994 Aug 22;261(3):237-47 PMID: 7813544
  35. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes.
    J Immunol. 2006 Feb 1;176(3):1848-59 PMID: 16424216
  36. Inducible cyclooxygenase may have anti-inflammatory properties.
    Nat Med. 1999 Jun;5(6):698-701 PMID: 10371510
  37. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells.
    Am J Physiol Cell Physiol. 2005 Sep;289(3):C557-63 PMID: 15901601
  38. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly.
    Oncogene. 2006 Jan 5;25(1):122-9 PMID: 16132039
  39. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4).
    J Pharmacol Exp Ther. 2002 Feb;300(2):385-92 PMID: 11805195
  40. Differential inside-out activation of beta2-integrins by leukotriene B4 and fMLP in human neutrophils.
    Exp Cell Res. 2004 Nov 1;300(2):308-19 PMID: 15474996
  41. Omega-3 fatty acids in inflammation and autoimmune diseases.
    J Am Coll Nutr. 2002 Dec;21(6):495-505 PMID: 12480795
  42. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors.
    J Exp Med. 1997 May 5;185(9):1693-704 PMID: 9151906
  43. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.
    J Exp Med. 2000 Oct 16;192(8):1197-204 PMID: 11034610
  44. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis.
    FASEB J. 2006 Feb;20(2):401-3 PMID: 16373400
  45. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression.
    Nat Immunol. 2006 Nov;7(11):1209-16 PMID: 17013391
  46. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells.
    J Immunol. 2003 Jun 15;170(12):6266-72 PMID: 12794159
  47. Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing.
    J Exp Med. 2007 Feb 19;204(2):245-52 PMID: 17242163
  48. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils.
    Biochemistry. 1995 Nov 7;34(44):14609-15 PMID: 7578068
  49. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors.
    J Biol Chem. 2000 Sep 8;275(36):27566-75 PMID: 10869343
  50. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages.
    J Biol Chem. 2006 Dec 15;281(50):38376-84 PMID: 17056601
  51. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells.
    J Immunol. 1996 Mar 15;156(6):2264-72 PMID: 8690917
  52. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense.
    J Biol Chem. 2005 Apr 15;280(15):15267-78 PMID: 15708862
  53. Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells.
    Kidney Int. 2006 Jan;69(2):248-56 PMID: 16408113
  54. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications.
    Nat Clin Pract Rheumatol. 2007 Jan;3(1):43-51 PMID: 17203008
  55. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis.
    Proc Natl Acad Sci U S A. 2005 May 24;102(21):7671-6 PMID: 15890784
  56. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release.
    J Exp Med. 1998 Apr 20;187(8):1285-94 PMID: 9547339
  57. Resolving the problem of persistence in the switch from acute to chronic inflammation.
    Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20647-8 PMID: 18093938
  58. Immune cell migration in inflammation: present and future therapeutic targets.
    Nat Immunol. 2005 Dec;6(12):1182-90 PMID: 16369557
  59. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
    Lancet. 1999 Aug 7;354(9177):447-55 PMID: 10465168
  60. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution.
    Histochem Cell Biol. 2004 Oct;122(4):305-21 PMID: 15322859
  61. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo.
    J Immunol. 2007 Nov 15;179(10):7021-9 PMID: 17982093
  62. Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation.
    FASEB J. 2006 Sep;20(11):1785-92 PMID: 16940150
  63. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation.
    Science. 1983 May 6;220(4597):568-75 PMID: 6301011
  64. Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor.
    Am J Respir Cell Mol Biol. 2006 Jan;34(1):65-72 PMID: 16141446
  65. Molecular circuits of resolution: formation and actions of resolvins and protectins.
    J Immunol. 2005 Apr 1;174(7):4345-55 PMID: 15778399
  66. A synthetic eicosanoid LX-mimetic unravels host-donor interactions in allogeneic BMT-induced GvHD to reveal an early protective role for host neutrophils.
    FASEB J. 2005 Feb;19(2):203-10 PMID: 15677343
  67. Transcellular conversion of endogenous arachidonic acid to lipoxins in mixed human platelet-granulocyte suspensions.
    Biochem Biophys Res Commun. 1988 Dec 15;157(2):801-7 PMID: 2849436
  68. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial.
    Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15178-83 PMID: 15471991
  69. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion.
    J Clin Invest. 1999 Aug;104(3):309-16 PMID: 10430612
  70. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation.
    J Biol Chem. 2007 Mar 30;282(13):9323-9334 PMID: 17244615
  71. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.
    J Exp Med. 2002 Oct 21;196(8):1025-37 PMID: 12391014
  72. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases.
    J Dent Res. 2003 Feb;82(2):82-90 PMID: 12562878
  73. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
    Nat Med. 2006 Sep;12(9):1056-64 PMID: 16951685
  74. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat.
    Circulation. 2006 Aug 29;114(9):929-35 PMID: 16908763
  75. Diminished lipoxin biosynthesis in severe asthma.
    Am J Respir Crit Care Med. 2005 Oct 1;172(7):824-30 PMID: 15961693
  76. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.
    Nat Immunol. 2004 Apr;5(4):388-92 PMID: 15034576
  77. Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin.
    Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9967-72 PMID: 9275235
  78. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis.
    Chem Biol. 2006 Nov;13(11):1193-202 PMID: 17114001
  79. Lipid mediator class switching during acute inflammation: signals in resolution.
    Nat Immunol. 2001 Jul;2(7):612-9 PMID: 11429545
  80. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation.
    J Biol Chem. 2003 Apr 25;278(17):14677-87 PMID: 12590139
  81. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development.
    J Clin Invest. 1996 Nov 15;98(10):2201-8 PMID: 8941635
  82. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase.
    Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2135-9 PMID: 14766977
  83. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.
    J Clin Invest. 1998 Feb 15;101(4):819-26 PMID: 9466977
  84. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury.
    Anesthesiology. 2001 Jun;94(6):1133-8 PMID: 11465607
  85. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine.
    Clin Sci (Lond). 1989 Aug;77(2):195-203 PMID: 2548801
  86. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages.
    J Immunol. 2000 Feb 15;164(4):1663-7 PMID: 10657608
  87. Resolvin D series and protectin D1 mitigate acute kidney injury.
    J Immunol. 2006 Nov 1;177(9):5902-11 PMID: 17056514
  88. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution.
    FASEB J. 2007 Oct;21(12):3162-70 PMID: 17496159
  89. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation.
    J Immunol. 2007 Mar 15;178(6):3912-7 PMID: 17339491
  90. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases.
    J Immunol. 2000 Mar 1;164(5):2660-6 PMID: 10679106
  91. Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis.
    J Exp Med. 2004 Feb 16;199(4):515-23 PMID: 14970178
  92. Release of inflammatory mediators from stimulated neutrophils.
    N Engl J Med. 1980 Jul 3;303(1):27-34 PMID: 6246431
  93. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers.
    J Clin Invest. 1993 Jul;92(1):75-82 PMID: 8326019
  94. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression.
    J Biol Chem. 2003 Oct 31;278(44):43807-17 PMID: 12923200
  95. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis.
    Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13375-80 PMID: 10557328
  96. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.
    Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9475-9 PMID: 7568157
  97. Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina.
    Biochem Biophys Res Commun. 1984 Dec 14;125(2):741-7 PMID: 6240268
  98. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function.
    Am J Physiol Renal Physiol. 2001 Nov;281(5):F887-99 PMID: 11592947
  99. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a 'stop' signaling switch for aspirin-triggered lipoxin A4.
    FASEB J. 1999 May;13(8):903-11 PMID: 10224233
  100. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo.
    Pharmacol Rev. 2006 Sep;58(3):463-87 PMID: 16968948
  101. Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism.
    Thromb Haemost. 2007 Jan;97(1):88-98 PMID: 17200775
  102. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes.
    Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13266-71 PMID: 12235371
  103. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis.
    Nat Med. 2007 Jul;13(7):868-873 PMID: 17589522
  104. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress.
    Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8491-6 PMID: 15152078
  105. Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing.
    FASEB J. 2007 Jul;21(9):2257-66 PMID: 17384141
  106. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia.
    Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3902-7 PMID: 11891303
  107. Mediator-lipidomics: databases and search algorithms for PUFA-derived mediators.
    J Lipid Res. 2005 Apr;46(4):790-802 PMID: 15722568
  108. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo.
    J Am Soc Nephrol. 2002 Oct;13(10):2497-507 PMID: 12239238
  109. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis.
    J Immunol. 2002 May 15;168(10):5260-7 PMID: 11994483
  110. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering.
    J Biol Chem. 2005 Dec 30;280(52):43079-86 PMID: 16216871
  111. Resolvin E1 and protectin D1 activate inflammation-resolution programmes.
    Nature. 2007 Jun 14;447(7146):869-74 PMID: 17568749
  112. Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils.
    J Exp Med. 1990 Nov 1;172(5):1451-7 PMID: 2172436
Article Info
Journal
Nature reviews. Immunology
Abbr.
Nat Rev Immunol
ISSN
1474-1741
DOI
10.1038/nri2294
Email
cnserhan@zeus.bwh.harvard.edu
Published
2008-05-00
Pages
349-61
Language
English
Region
England
NLM ID
101124169
PMCID
PMC2744593
Subset
IM
Grants
NIDDK NIH HHS · R01 DK074448 · United States
NIGMS NIH HHS · GM38765 · United States
NIDCR NIH HHS · P50-DE016191 · United States
NIGMS NIH HHS · R01 GM038765 · United States
NIDDK NIH HHS · R01 DK074448-03 · United States
NIGMS NIH HHS · R37 GM038765-21 · United States
NIDCR NIH HHS · P50 DE016191 · United States
NIGMS NIH HHS · R37 GM038765 · United States
NIDDK NIH HHS · DK074448 · United States
NIDCR NIH HHS · P50 DE016191-04 · United States
External Links
PubMed source DOI: 10.1038/nri2294 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2